Pasar al contenido principal

Cristina Solé Marce

I am a Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute. Previously, I held a postdoctoral research position in the same unit, and during my PhD, I conducted research at the University of Durham (Durham, UK), Anacor Pharmaceuticals (California, USA), and Rovira i Virgili University (Tarragona, Catalonia). I hold a dual degree in Chemistry and Biochemistry, and during these studies, I also conducted research at the University of Reading (Reading, UK) and the University of the Balearic Islands (Mallorca, Spain). My research career has focused on autoimmune diseases, particularly on the pathogenesis of lupus and antiphospholipid syndrome, as well as the synthesis and mechanisms of action of biological drugs.

Instituciones de las que forman parte

Investigador/a principal
Reumatología
Vall Hebron Institut de Recerca

Cristina Solé Marce

Instituciones de las que forman parte

Investigador/a principal
Reumatología
Vall Hebron Institut de Recerca

I am a Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute. Previously, I held a postdoctoral research position in the same unit, and during my PhD, I conducted research at the University of Durham (Durham, UK), Anacor Pharmaceuticals (California, USA), and Rovira i Virgili University (Tarragona, Catalonia). I hold a dual degree in Chemistry and Biochemistry, and during these studies, I also conducted research at the University of Reading (Reading, UK) and the University of the Balearic Islands (Mallorca, Spain). My research career has focused on autoimmune diseases, particularly on the pathogenesis of lupus and antiphospholipid syndrome, as well as the synthesis and mechanisms of action of biological drugs.

Since 2021, I am Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute (VHIR). Previously, I spent six years as a postdoctoral researcher in the same unit. Since then, our focus has been on research aimed at improving patients' lives, whether through the identification of new biomarkers that inform us about their condition without the need for invasive techniques, or through the discovery of the effects of new drugs and/or the molecular pathways involved in the development of different clinical manifestations. In this regard, we have already published several papers in internationally recognized journals and have been invited to prestigious conferences (ACR, EULAR, etc.).

Before joining VHIR, I graduated with dual degrees in Chemistry and Biochemistry from Rovira i Virgili University, where I achieved the highest academic record in both programs. I then began my PhD, focusing on the enantioselective synthesis of drugs, while simultaneously completing a master’s degree in "Synthesis and Catalysis" at Rovira i Virgili University.

I have completed various research stays at national, European, and international levels. Specifically, I worked at the University of the Balearic Islands with Dr. Palou's team, researching the regulation of metabolism via ghrelin/leptin. I then conducted research at Reading University with Dr. Katja Strohfeldt, synthesizing anticancer drugs based on germanium. Additionally, I worked at Durham University with Dr. Andy Whiting, exploring new enantio- and diastereo-selective pathways for drug synthesis. Finally, before joining my current team, I worked at Anacor Pharmaceuticals in Palo Alto (California, USA), both in the chemical synthesis and biological departments.

Proyectos

Teràpia gènica amb miRNAs d'interferència com a nova alternativa de tractament al lupus eritematós discoide (LED)

IP: Cristina Solé Marce
Colaboradores: -
Entidad financiadora: Institut d'Estudis Catalans (IEC)
Financiación: 6000
Referencia: IEC/PREMI/2022/SOLE
Duración: 01/04/2023 - 31/12/2024

Novel therapeutic topical approach for discoid lupus cutaneous (DLE) treatment

IP: Cristina Solé Marce
Colaboradores: Berta Ferrer Fábrega, Gloria Aparicio Español
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 99099
Referencia: PI21/01869
Duración: 01/01/2022 - 31/12/2025

Las células T del receotir del autoantígeno quimérico (CAAR-Tcell) como nueva terapia dirigida para la nefritis lúpica.

IP: Josefina Cortes Hernandez
Colaboradores: José Ordi Ros, Cristina Solé Marce
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 122815
Referencia: PI18/01917
Duración: 01/01/2019 - 30/06/2023

Investigación del mecanismo de acción de la Talidomida en el Lupus Discoide para el desarrollo de nuevas terapias

IP: Josefina Cortes Hernandez
Colaboradores: Jordi Mollet Sánchez, Cristina Solé Marce
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 104665
Referencia: PI15/02145
Duración: 01/01/2016 - 31/12/2019

Noticias relacionadas

La media para llegar al diagnóstico de una enfermedad minoritaria es de 5 años. Vall d'Hebron, el centro del Estado con más ensayos clínicos autorizados, se suma ahora a la nueva alianza europea ERDERA para coordinar y agilizar la investigación.

La Semana de la Ciencia se dirige a todos los públicos y tiene como objetivos hacer accesible la ciencia y la tecnología a la ciudadanía y fomentar las vocaciones científicas entre los más jóvenes.

Una veintena de investigadores e investigadoras participan en charlas y talleres para acercar la ciencia a todo el mundo.

Profesionales relacionados

Ana Maria Rodriguez Arana

Ana Maria Rodriguez Arana

Investigador/a principal
Imagen Médica Molecular
Leer más
Júlia Laborda Aylagas

Júlia Laborda Aylagas

Técnico de investigación
Medicina Materna y Fetal
Leer más
Patricia García Ortega

Patricia García Ortega

Técnico de investigación
Leer más
Ramon Gonzalez Rioja

Ramon Gonzalez Rioja

Investigador predoctoral
Nanopartículas Farmacocinéticas
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.